Stock Research for BCLI

BCLI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BCLI Stock Chart & Research Data

The BCLI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BCLI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BCLI Due diligence Resources & Stock Charts

The BCLI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BCLI Detailed Price Forecast - CNN Money CNN View BCLI Detailed Summary - Google Finance
Yahoo View BCLI Detailed Summary - Yahoo! Finance Zacks View BCLI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View BCLI Trends & Analysis - Trade-Ideas Barrons View BCLI Major Holders - Barrons
NASDAQ View BCLI Call Transcripts - NASDAQ Seeking View BCLI Breaking News & Analysis - Seeking Alpha
Spotlight View BCLI Annual Report - CompanySpotlight.com OTC Report View BCLI OTC Short Report - OTCShortReport.com
TradeKing View BCLI Fundamentals - TradeKing Charts View BCLI SEC Filings - Bar Chart
WSJ View Historical Prices for BCLI - The WSJ Morningstar View Performance/Total Return for BCLI - Morningstar
MarketWatch View the Analyst Estimates for BCLI - MarketWatch CNBC View the Earnings History for BCLI - CNBC
StockMarketWatch View the BCLI Earnings - StockMarketWatch MacroAxis View BCLI Buy or Sell Recommendations - MacroAxis
Bullish View the BCLI Bullish Patterns - American Bulls Short Pains View BCLI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View BCLI Stock Mentions - StockTwits PennyStocks View BCLI Stock Mentions - PennyStockTweets
Twitter View BCLI Stock Mentions - Twitter Invest Hub View BCLI Investment Forum News - Investor Hub
Yahoo View BCLI Stock Mentions - Yahoo! Message Board Seeking Alpha View BCLI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for BCLI - SECform4.com Insider Cow View Insider Transactions for BCLI - Insider Cow
CNBC View BCLI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BCLI - OTC Markets
Yahoo View Insider Transactions for BCLI - Yahoo! Finance NASDAQ View Institutional Holdings for BCLI - NASDAQ


Stock Charts

FinViz View BCLI Stock Insight & Charts - FinViz.com StockCharts View BCLI Investment Charts - StockCharts.com
BarChart View BCLI Stock Overview & Charts - BarChart Trading View View BCLI User Generated Charts - Trading View




Latest Financial News for BCLI


BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
Posted on Tuesday April 16, 2024

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the promotion of Dr. Bob Dagher to Executive Vice President and Chief Medical Officer. In addition, after four years of maintaining top executive roles, Dr. Stacy Lindborg stepping down from the role of Co-CEO and will remain with BrainStorm as a member of its Board of Directors. These strategic management changes are being made as the Company prep


BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…
Posted on Thursday April 11, 2024

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT Business Update Receives SPA Agreement with FDA On April 9, 2024, BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) announced that it received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn™ in amyotrophic lateral sclerosis


BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
Posted on Thursday April 11, 2024

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases, today announced that it received a notification letter (the "Notification Letter on Compliance") on April 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq"), indicating that the Company has regained compliance with the minimum market value of listed securities requirement set forth under Nasdaq Listing Rule 5550(b)(2) (t


BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Posted on Wednesday April 10, 2024

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announced the peer-reviewed publication of Phase 3 biomarker data in Muscle and Nerve. The paper, entitled "Debamestrocel multimodal effects on biomarker pathways in amyotrophic lateral sclerosis are linked to clinical outcomes", can be found online through the Muscle and Nerve website. This study suggests that debamestrocel or NurOwn®, an investigational cell therapy


Stock Market & Investing Books

Enter a stock symbol to view the stock details.